Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264117 | 0.85 | TEK (0.61) | CASP6TEKKDRLCKBRAF | |
| SCHEMBL1265107 | 0.83 | TEK (0.49) | CASP6TEKKDRLCKBRAF | |
| SCHEMBL1264844 | 0.81 | TEK (0.60) | CASP6TEKKDRLCKBRAF | |
| SCHEMBL2650530 | 0.75 | MAP4K4 (0.43) | CASP6MAPK14 | |
| SCHEMBL1265625 | 0.74 | TEK (0.48) | CASP6TEKKDRLCKBRAF | |
| SCHEMBL1264109 | 0.72 | KDR (0.83) | TEKKDRLCKBRAFMAPK14 | |
| SCHEMBL1263934 | 0.71 | KDR (0.64) | TEKKDRLCKBRAFMAPK14 | |
| SCHEMBL24885812 | 0.71 | RET (0.49) | LCKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3822515 | 0.71 | TEK (0.46) | TEKKDRLCKBRAFMAPK14 | |
| SCHEMBL30078138 | 0.71 | RET (0.49) | LCKPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | CASP6 2977/4885TEK 215/4885KDR 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.